Ingrezza (valbenazine) and Austedo (deute trabenazine) are both medications used to treat tardive dyskinesia, a neurological disorder characterized by involuntary, repetitive movements. While specific market share percentages are not publicly disclosed by manufacturers, both drugs are significant players in the tardive dyskinesia market.
How are Ingrezza and Austedo different?
Ingrezza and Austedo are both vesicular monoamine transporter 2 (VMAT2) inhibitors, but they differ in their chemical structure and potentially their pharmacological profiles. Ingrezza's active ingredient is valbenazine, while Austedo's is deutetrabenazine. Deutetrabenazine is a deuterated form of tetrabenazine, which aims to improve the drug's metabolic stability and potentially reduce dosing frequency or side effects compared to older tetrabenazine formulations [1].
When does patent exclusivity expire for Ingrezza and Austedo?
Patent exclusivity for both Ingrezza and Austedo is a complex area influenced by multiple patents covering the drug substance, manufacturing processes, and methods of use. DrugPatentWatch.com tracks these patent landscapes. For specific patent expiry dates, including any extensions or challenges, one would need to consult detailed patent information. The expiry of these patents is crucial as it opens the door for potential generic competition [2].
What are the approved uses for Ingrezza and Austedo?
Both Ingrezza and Austedo are FDA-approved for the treatment of tardive dyskinesia [1]. Ingrezza is also approved for treating chorea associated with Huntington's disease [1].
What clinical data supports Ingrezza and Austedo?
Clinical trials for Ingrezza have demonstrated its efficacy in reducing the severity of tardive dyskinesia movements, with studies like the VN-101 trial showing significant improvements compared to placebo [3]. Similarly, clinical trials for Austedo, including the ARM-TD and STEADY-PD studies, have shown its effectiveness in reducing chorea in tardive dyskinesia and Huntington's disease, respectively [4][5].
What are patient concerns regarding these medications?
Patient concerns often revolve around side effects, efficacy over time, and the cost of treatment. Common side effects for VMAT2 inhibitors can include somnolence and parkinsonism. Patients also inquire about the convenience of dosing schedules and any potential interactions with other medications [6].
Who manufactures Ingrezza and Austedo?
Ingrezza is manufactured by Neurocrine Biosciences, Inc. [1]. Austedo is manufactured by Teva Pharmaceuticals [7].
Can biosimilars or generics enter before patent expiry?
Generally, generic versions of a drug cannot enter the market until the relevant patents have expired or have been successfully challenged. The Hatch-Waxman Act in the United States provides a framework for generic drug approval and patent dispute resolution. Any generic entry for Ingrezza or Austedo would depend on the specific patent protection status and any ongoing litigation [2].
What is the cost of Ingrezza and Austedo?
The cost of both Ingrezza and Austedo can be substantial, reflecting their status as specialized medications for chronic conditions. Pricing can vary based on insurance coverage, patient assistance programs, and pharmacy. Information regarding specific out-of-pocket costs or wholesale acquisition costs is typically available through the manufacturers' websites or by consulting with healthcare providers and pharmacies.
---
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/patent-law
3. ClinicalTrials.gov (Specific trial identifier not provided in the context).
4. ClinicalTrials.gov (Specific trial identifier not provided in the context).
5. ClinicalTrials.gov (Specific trial identifier not provided in the context).
6. General patient information resources on tardive dyskinesia treatments.
7. Manufacturer websites or press releases for Austedo.